Gonadorelin

Dosing evidence

Pulsatility warning: "pulsatile gonadorelin" has a specific meaning in reproductive endocrinology. Historical therapy used frequent small doses designed to reproduce hypothalamic GnRH pulses. A Monday/Wednesday/Friday injection schedule, a once-daily injection or even three manual injections per day are not equivalent to physiologic pulsatile replacement.

The pulse pattern matters as much as the dose

Natural GnRH is released in brief pulses, not continuously, and that timing pattern is fundamental to normal reproductive endocrine function. Appropriate intermittent GnRH stimulation promotes pituitary LH and FSH secretion, while prolonged or sustained receptor stimulation can lead to GnRH-receptor desensitization and reduced gonadotropin output.

More frequent does not mean more effective: the pituitary responds to the pattern of GnRH exposure. A schedule such as 100-200 mcg three times per day is not a good approximation of normal physiology merely because it is frequent, and 50-150 mcg Monday/Wednesday/Friday is not pulsatile in the physiologic sense. The medical concept of pulsatile GnRH involves small automated doses repeated about every 60-120 minutes, not several isolated injections per week.

Gonadorelin has strong human evidence when used to reproduce missing hypothalamic GnRH signaling through pulsatile administration. Modern intermittent SC bolus protocols are different exposures with a much weaker evidence base.

Dose at a glance

There is no single gonadorelin dose without defining the purpose and exposure pattern. A "typical dose of 100 mcg" or "typical dose of 100-200 mcg" is not supported.

Historical pulsatile human therapy

Pulsatile GnRH therapy was designed to imitate the normal hypothalamic pulse generator. Treatment used an infusion pump delivering very small doses at short regular intervals. The central human therapeutic anchor is 5 mcg every 90 minutes by SC or IV pulsatile pump, with individualized doses of about 1-20 mcg per pulse. Historical programs explored a wider range, but the clinical model remained small microgram pulses repeated at short intervals rather than large intermittent boluses.

Diagnostic gonadorelin

Gonadorelin has been used as a GnRH stimulation test. A single bolus of about 100 mcg IV or SC has legitimate human diagnostic precedent for assessing pituitary LH/FSH response. A single diagnostic 100 mcg bolus does not validate repeated 100 mcg doses during TRT.

Community protocols

Community protocols are internally inconsistent and are not converging on the historic clinical physiology. Current pages span a few injections weekly, daily injections, multiple daily injections and escalating schedules. The protocols described below have not been validated in clinical trials.

• Three times daily: 100-200 mcg three times daily, often for 4 weeks. Community intermittent protocol; it does not reproduce physiologic replacement.
• Monday/Wednesday/Friday escalation: 50, then 100, then 150 mcg. Sometimes called a "pulsed protocol", but it is a community intermittent bolus protocol. Every injection technically produces a pulse, yet in reproductive endocrinology pulsatile GnRH therapy means repeated short-interval administration that replicates hypothalamic secretion, which M/W/F dosing does not do.
• PeptideDosages: about 50-200 mcg per injection, often 2-3 times weekly, with some pages extending toward 250 mcg.

Does three times daily mimic natural pulses?

Poorly. Pulsatile GnRH therapy uses small doses about every 60-120 minutes. A 90-minute pulse interval produces about 16 pulses a day; a three-times-daily protocol produces 3 exposures a day. Several manual injections per day may create intermittent GnRH exposure but do not reproduce physiologic pulsatility.

Does 2-3 times weekly make sense?

It may generate short, transient LH/FSH responses. There is no strong evidence that 50-200 mcg 2-3 times weekly maintains continuous fertility-related gonadotropin support. Given gonadorelin's brief action, large gaps between doses are biologically very different from pulsatile replacement. This is community and TRT practice, not physiologic pulsatile replacement.

Once-daily dosing

A dose can induce a temporary LH/FSH response. That does not mean once-daily dosing reproduces normal HPG-axis signaling across the day. It is intermittent pharmacologic stimulation.

Continuous gonadorelin and desensitization

Continuous or sustained GnRH-receptor stimulation can desensitize pituitary gonadotrophs and suppress LH/FSH. This is a fundamental reason pulsatile and continuous GnRH signaling have opposite endocrine consequences. The exact desensitization risk depends on dose, exposure pattern and formulation, and native GnRH and long-acting GnRH agonists do not have identical pharmacokinetics. The claim that "any incorrectly timed dose causes chemical castration" goes beyond the evidence.

Receptor reset

There is no evidence-based 4-week reset, 8-week reset, weekend washout or receptor recovery cycle. The real biological issue is pulse pattern.

Timing at a glance

What matters clinically is pulse frequency and endocrine context.

Human pharmacokinetics

Gonadorelin is cleared rapidly. Historical human IV data describe biexponential disappearance: an initial half-life of about 2-10 minutes and a terminal half-life of about 10-40 minutes. Human pharmacokinetics are biphasic, so "half-life = 2 minutes" is an oversimplification.

Subcutaneous pharmacology: SC administration has shown bioavailability and pituitary LH/FSH response in humans. Historical relative SC/IV bioavailability estimates varied by dose and study conditions. That does not establish pharmacokinetic equivalence between SC pump micro-pulses and large intermittent community boluses.

Renal function: the kidney is a major route of gonadorelin metabolism and clearance. Historical human data indicate that renal failure can prolong half-life and reduce clearance. This is an established pharmacokinetic consideration.

Cycle length

There is no single gonadorelin cycle.

• Women with hypothalamic amenorrhea: treatment was evaluated over consecutive weeks until ovulation and could continue briefly after ovulation for luteal support.
• Male CHH: treatment often lasts months to years, particularly when puberty or spermatogenesis is being induced.
• Community TRT adjunct: no validated cycle.

A generic 4-8 week gonadorelin cycle is not a clinical rule.

Expected results timeline

Acute response: LH and FSH can rise fairly quickly after a stimulation dose, which is why gonadorelin has been useful diagnostically. This shows acute pituitary responsiveness, not long-term fertility restoration after one injection.

Female pulsatile therapy: outcomes are measured across treatment cycles, commonly over several weeks.

Historical product guidance generally expected a response within about 2-3 weeks.

Male hypogonadotropic hypogonadism:

Testosterone may normalize earlier than full spermatogenesis, and restoring sperm production can take months because spermatogenesis is a slow biological process. A generic "weeks 1-4" peptide timeline is misleading for gonadorelin.

Medical literature and study context

What is gonadorelin?

Gonadorelin is the synthetic form of the naturally occurring human hormone gonadotropin-releasing hormone (GnRH), a 10-amino-acid peptide released by the hypothalamus.

Sequence: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂

Its main target is the GnRH receptor (GnRHR) on pituitary gonadotroph cells. Activating that receptor releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which regulate ovarian and testicular function, including ovulation, estrogen production, testosterone production, spermatogenesis and fertility.

Gonadorelin acts upstream of the gonads. It does not directly replace testosterone, LH, FSH or hCG.

How well studied is gonadorelin?

It is very well studied biologically and historically in reproductive medicine.

Overall evidence rating: strong human reproductive-endocrine evidence, with much weaker evidence for modern community and TRT dosing patterns.

Historical FDA approval

FDA records show that gonadorelin acetate, under the trade name Lutrepulse, received U.S. marketing approval on October 10, 1989 for induction of ovulation in women with hypothalamic amenorrhea associated with deficient or abnormal endogenous GnRH secretion. Lutrepulse was used for pulsatile ovulation induction and is no longer marketed in the United States. FDA records also document historical gonadorelin products such as Factrel, a human diagnostic product that was later discontinued.

Gonadorelin therefore has a legitimate medical history. That history is specific: the strong evidence is for carefully timed reproductive-endocrine protocols, especially pulsatile delivery. Current compounded gonadorelin products and modern TRT protocols are not FDA-approved regimens, and the historical approval does not validate arbitrary modern peptide-vial schedules.

Modern pulsatile research

Pulsatile GnRH remains clinically relevant. A multicenter randomized, double-blind, placebo-controlled Phase 3 study evaluated subcutaneous pulsatile gonadorelin acetate delivered through an OmniPod pump in women with primary amenorrhea and hypogonadotropic hypogonadism, at 10, 15 and 20 mcg per pulse. This program continued to use small, frequent pump-delivered pulses rather than the larger intermittent injections of community protocols.

ClinicalTrials.gov also lists a Phase 1 pharmacokinetic study of subcutaneous pulsatile GnRH delivered through an OmniPod system in healthy female subjects. It supports renewed development of pulsatile GnRH for hypothalamic amenorrhea, but it is a PK study and not an efficacy trial in women with hypothalamic amenorrhea.

2022 functional hypothalamic amenorrhea cohort

A 25-year retrospective cohort published in 2022 evaluated 66 women undergoing 212 pulsatile GnRH treatment cycles for functional hypothalamic amenorrhea. Reported outcomes included about:

• 96% ovulation per cycle
• 65.9% live birth per treatment
• 75% monofollicular ovulation
• 1.6% twin pregnancy rate

No significant adverse effects were reported in the cohort. This is meaningful modern observational evidence supporting pulsatile GnRH therapy in appropriately selected hypothalamic amenorrhea.

Historical female evidence

The historical Lutrepulse clinical database included 268 women receiving gonadorelin acetate or related formulations through programmable pulsatile pumps, by IV, SC or both routes. Doses ranged broadly, but 90 minutes was the most common pulse interval. Among 48 women with primary hypothalamic amenorrhea, 45 of 48 (94%) ovulated. Among those wishing to become pregnant, 25 of 43 (58%) became pregnant. This is substantial direct human therapeutic evidence, and a blanket rating of "limited" does not describe the established reproductive indication.

Male congenital hypogonadotropic hypogonadism

A 2019 study comparing a pulsatile gonadorelin pump with conventional gonadotropin treatment in men with congenital hypogonadotropic hypogonadism (CHH) found earlier spermatogenesis and favorable testosterone restoration in the pulsatile-gonadorelin group. Modern male CHH programs continue to use pulse therapy: published regimens use about 7-15 mcg per pulse every 90 minutes, and other studies use about 5-10 mcg every 90 minutes, adjusted to hormonal and clinical response. A 2025 infant CHH study used 5 mcg every 90 minutes SC for about 3-5 months with a pulsatile pump.

This is real human therapeutic evidence, specifically in hypothalamic GnRH deficiency with a responsive pituitary and gonadal axis. It is not evidence for general male hormone optimization.

What may gonadorelin help with?

Hypothalamic amenorrhea: one of its best-established uses. When the hypothalamus fails to produce adequate GnRH pulses but the pituitary and ovaries can still respond, pulsatile gonadorelin can recreate the missing upstream signal. Strong historical human evidence.

Hypogonadotropic hypogonadism: pulsatile GnRH may restore LH, FSH, testosterone, testicular growth and spermatogenesis when the disorder is primarily hypothalamic rather than pituitary or gonadal. Meaningful human evidence.

Male fertility: proper pulsatile GnRH can restore endogenous gonadotropin secretion and support spermatogenesis in selected men with congenital or hypothalamic GnRH deficiency. That is legitimate fertility medicine, and a different clinical question from whether gonadorelin preserves fertility on TRT.

The defect location matters

Gonadorelin works best when the reproductive-axis defect is upstream at the hypothalamus and the pituitary and gonads can still respond.

• Hypothalamus missing GnRH: gonadorelin can replace the missing signal.
• Pituitary unable to respond: gonadorelin may fail.
• Gonads unable to respond: gonadorelin may raise gonadotropins without restoring normal gonadal function.

Gonadorelin during TRT

Here the evidence becomes much weaker. Exogenous testosterone creates negative feedback at the hypothalamus and pituitary, suppressing GnRH, LH and FSH, and can reduce intratesticular testosterone, spermatogenesis and fertility. A few gonadorelin injections per week do not recreate the normal GnRH pulse generator. TRT-adjunct gonadorelin is a clinic and community practice with a physiologic rationale; it is not equivalent to established pulsatile GnRH fertility therapy.

Why CHH evidence cannot simply be applied to TRT: both states can produce low LH/FSH, but for different reasons. In CHH the problem is insufficient endogenous GnRH, and the solution is to replace GnRH in physiologic pulses. On TRT an intact feedback system is deliberately suppressed by exogenous androgen, and an occasional GnRH bolus does not remove that negative-feedback environment. Successful pulsatile therapy in CHH does not establish that a few gonadorelin injections each week maintain the HPG axis during TRT.

Evidence that pulsatile gonadorelin restores fertility in hypothalamic GnRH deficiency does not prove that intermittent gonadorelin reliably preserves fertility, intratesticular testosterone or sperm production during suppressive testosterone therapy. Intermittent gonadorelin may produce temporary LH/FSH responses in some men, but evidence that a few injections per week reliably preserve sperm production is much weaker.

Gonadorelin versus hCG

Gonadorelin acts at the pituitary GnRH receptor to stimulate endogenous LH and FSH, if the pituitary remains responsive. hCG acts mainly as an LH-receptor agonist at the testes.

• Gonadorelin: pituitary, then LH/FSH, then testes
• hCG: LH receptor on the testes directly

This explains why the two are not interchangeable during testosterone-induced pituitary suppression, and why hCG can still work downstream when the pituitary is suppressed. Gonadorelin is not a drop-in replacement for hCG.

Research at a glance

Summary

Bottom line

The core molecule and physiology of gonadorelin are extremely well established: it is synthetic human GnRH, and GnRH control of pituitary LH and FSH is foundational reproductive endocrinology. It also has a real therapeutic history, including FDA approval of Lutrepulse in 1989 for ovulation induction in hypothalamic amenorrhea.

That history does not support the community protocols now in circulation. Physiologic GnRH replacement used much more frequent, smaller, pump-delivered pulses, with a central anchor of 5 mcg about every 90 minutes and individualized doses of about 1-20 mcg per pulse. The body does not release GnRH three times a day, and Monday/Wednesday/Friday dosing is an intermittent bolus schedule. Community pages publish much larger injections, commonly 50-200 mcg several times weekly, alongside daily or multiple-daily schedules; this is a set of community schedules that has drifted away from the best-established human model, not a clinical consensus.

Sustained non-pulsatile exposure can reduce pituitary responsiveness, but an occasional native gonadorelin bolus, cleared within minutes, is not equivalent to sustained leuprolide exposure. The strongest human evidence supports a fundamentally different exposure pattern from the protocols circulating in peptide communities. Gonadorelin has strong human evidence when used to reproduce missing hypothalamic GnRH signaling through pulsatile administration; modern intermittent SC bolus protocols are different exposures with a much weaker evidence base.

Protocol logic check

Storage

Formulation and stability

Historical gonadorelin pharmaceutical products had standardized formulations and delivery systems. Lutrepulse came as lyophilized gonadorelin acetate and reconstituted for programmable pump use according to the product's own instructions. Current peptide-vial gonadorelin does not inherit those stability specifications. Storage, dilution and beyond-use dating depend on the exact formulation, and historical Lutrepulse or Factrel data do not transfer to a modern compounded or research vial.

Veterinary product rules do not apply

U.S. product databases contain veterinary gonadorelin products, including cattle formulations with their own preservative systems and post-puncture instructions. Those instructions do not establish stability or dosing for compounded human peptide vials.

Contraindications & cautions

Gonadorelin has considerably more human safety experience than many experimental peptides, but safety depends on indication, dose, route, sex, ovarian status, endocrine disease and exposure pattern. There is no universal modern FDA contraindication list outside a specific product label and indication.

Pregnancy

Pregnancy is not a general indication for gonadorelin. Historical Lutrepulse therapy was sometimes continued briefly after induced ovulation for luteal support, and limited first-trimester historical exposure did not identify an apparent gonadorelin-attributable fetal signal in the available follow-up. This does not extend to elective gonadorelin use during pregnancy. Pregnancy considerations are specific to the indication and treatment stage.

Breastfeeding

Historical labeling stated that it was unknown whether gonadorelin is excreted in human milk, and there was no established nursing indication. Use is not established.

Pituitary disease

Gonadorelin requires pituitary responsiveness, so known pituitary disease can alter the response and requires condition-specific endocrine evaluation. Historical fertility labeling included conditions such as pituitary prolactinoma when pregnancy itself could worsen the disease. Pituitary adenoma is a condition-specific caution, not a blanket absolute contraindication.

GnRH-receptor mutations

A severe loss-of-function mutation in GnRHR can make exogenous GnRH ineffective because the pituitary cannot respond normally. This is a predictor of nonresponse rather than a formal contraindication.

PCOS

PCOS is a distinct cause of anovulation and is not the classic hypothalamic GnRH-deficiency indication for pulsatile gonadorelin. It is not the established indication, but it is not a universal absolute contraindication either.

Hormone-sensitive cancer

Raising LH/FSH and downstream sex-steroid production can matter in hormone-sensitive disease. This is an important disease-specific clinical caution.

Relevant screening factors

• whether the defect is hypothalamic, pituitary or gonadal
• pituitary responsiveness
• fertility goal
• ovarian response, where applicable
• pregnancy context
• renal function
• pulse interval
• exact formulation and product quality

Possible side effects

Documented historical human findings

• injection-site irritation
• superficial thrombophlebitis
• catheter or infusion-site problems
• headache
• nausea
• abdominal symptoms
• increased menstrual bleeding in fertility contexts

Adverse reactions in historical fertility programs were usually related to parenteral administration and the reproductive treatment context.

Antibody formation

Rare anti-GnRH antibodies have been documented during prolonged exposure. This is rare documented immunogenicity, not a common expected side effect.

Hypersensitivity and anaphylaxis

Rare hypersensitivity and anaphylactic reactions have been reported with gonadorelin preparations.

Ovarian hyperstimulation syndrome (OHSS)

OHSS is possible during ovulation induction. Historical pulsatile GnRH data describe it as rare, generally reported in less than 1% of treatment experience. OHSS is a recognized fertility-treatment risk, but pulsatile GnRH programs reported it infrequently and generally less prominently than gonadotropin-based ovarian stimulation; its risk is not comparable to exogenous FSH.

Multiple pregnancy

Multiple pregnancy is possible because more than one follicle can develop. Careful dose control and ultrasound monitoring were part of historical fertility treatment. This is an established fertility-treatment risk.

Priapism

Rare priapism appears in historical male gonadorelin safety information. It is a rare historical human report.

Effects that are not established

Testicular ache: no strong clinical source establishes testicular sensitivity or ache as a characteristic gonadorelin adverse effect. Community reports exist, but causality is uncertain.

Mood and libido fluctuations: subjective symptoms may occur during changing reproductive-hormone states, but a predictable gonadorelin-specific "trough" syndrome caused by testosterone oscillations between doses has not been established.

Compatibility

Commonly paired with

• hCG: gonadorelin acts at the pituitary (GnRHR, then LH/FSH); hCG acts at the testis (LH/CG receptor, then Leydig-cell stimulation). They are mechanistically distinct reproductive therapies, not proven interchangeable or automatically synergistic.
• Gonadotropins / FSH / hMG: in reproductive medicine, pulsatile GnRH and exogenous gonadotropin therapy are alternative or condition-specific approaches. One restores the upstream pituitary command; the other supplies downstream gonadotropin activity. These are formal endocrine regimens, not peptide "stacks".
• Kisspeptin: acts one level higher, stimulating endogenous GnRH neurons, while gonadorelin directly replaces the GnRH signal. Mechanistically related and potentially redundant; commonly paired, but controlled combination efficacy is unproven and no validated combination protocol exists.
• Testosterone: when exogenous testosterone is already suppressing the HPG axis, gonadorelin is not a proven way to "keep the pituitary active". Common off-label and clinic combination; controlled fertility-preservation evidence is not established.

Same-syringe compatibility

There is no universal evidence supporting physical or chemical compatibility between gonadorelin and hCG, testosterone, kisspeptin, FSH or other injectable peptides. Concurrent use does not establish same-syringe compatibility.

Regulatory status

Historical FDA approval

Yes. Gonadorelin acetate (Lutrepulse) received FDA marketing approval in 1989 for hypothalamic amenorrhea. A separate human gonadorelin hydrochloride product, Factrel, was historically approved for diagnostic use and later discontinued. A current veterinary product may use the Factrel trade name; its label is a different product from the historical human Factrel label.

Current U.S. product

No currently marketed FDA-approved human gonadorelin product has been identified. A discontinued product was still an approved product, and a historical approval does not make a current compounded product approved.

FDA 503B compounding status

The most recent FDA 503B bulk-substance category list located, dated March 21, 2025, lists gonadorelin acetate under 503B Category 1: Bulk Drug Substances Under Evaluation, with a notation that it is a component of an FDA-approved drug. This is the 503B list, not 503A, and Category 1 does not mean FDA has approved a compounded gonadorelin product or protocol.

FDA 2026 warning letter

In 2026 FDA issued a warning letter to a seller marketing a product as gonadorelin with claims involving testosterone production and spermatogenesis. FDA treated that product as an unapproved new drug and emphasized the risks of unapproved injectable products. This does not mean the gonadorelin molecule was never approved; it means that seller's product and claimed uses were not covered by an approved application. Historical approval of an ingredient does not extend to every modern research vial sold under the same name.

WADA status

The 2026 WADA Prohibited List names gonadotrophin-releasing hormone (GnRH, gonadorelin) and related releasing factors within the testosterone-stimulating peptide category for males. In competitive sport, gonadorelin is prohibited for male athletes.

Sources

1. U.S. Food and Drug Administration. Lutrepulse (gonadorelin acetate) approval, October 10, 1989, and historical labeling and clinical database.
2. U.S. Food and Drug Administration. Factrel (gonadorelin hydrochloride): historical human diagnostic product records.
3. Phase 3 multicenter randomized, double-blind, placebo-controlled study of subcutaneous pulsatile gonadorelin acetate via OmniPod in women with primary amenorrhea and hypogonadotropic hypogonadism.
4. ClinicalTrials.gov. Phase 1 pharmacokinetic study of subcutaneous pulsatile GnRH delivered by OmniPod in healthy female subjects.
5. Retrospective 25-year cohort of pulsatile GnRH therapy in functional hypothalamic amenorrhea (66 women, 212 cycles), 2022.
6. Comparison of pulsatile gonadorelin pump therapy with gonadotropin therapy in men with congenital hypogonadotropic hypogonadism, 2019.
7. Pulsatile GnRH therapy in infants with congenital hypogonadotropic hypogonadism, 2025.
8. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503B: categories list, March 21, 2025.
9. U.S. Food and Drug Administration. Warning letter to a seller of products marketed as gonadorelin, 2026.
10. World Anti-Doping Agency. 2026 Prohibited List.
11. PeptideDosages. Gonadorelin community protocol pages.